Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Prognosis
Urokinase-type plasminogen activator is prognostic in breast cancer
May 13th, 2004
Urokinase-type plasminogen activator (UPA) and its inhibitor PAl-l are novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. "Urokinase-type plasminogen activator (uPA) and its inhibitor, PAI-I, play a key role in tumor invasion and metastasis. They were the first novel tumor biological factors to be validated at the highest level of evidence (LOE 1) regarding their clinical utility in breast cancer. Their antigen levels are determined in tumor tissue extracts by standardized, quality-assured immunometric assays (ELISA). "Since the late 1980s, numerous independent studies have demonstrated that patients with low...
Source: Women's Health Weekly (2004-05-13)
|
